TITLE

S*BIO/UNIVERSITY OF SINGAPORE PARTNER ON TUMOR BIOAMARKER

PUB. DATE
July 2007
SOURCE
Worldwide Biotech;Jul2007, Vol. 19 Issue 7, p7
SOURCE TYPE
Trade Publication
DOC. TYPE
Article
ABSTRACT
The article focuses on the two-year research partnership forged by S*BIO Pte Ltd. with the National University Hospital-National University of Singapore Tissue Repository (NUH-NUS TR). The partnership is aimed at conducting biomarker research and at evaluating the responsiveness of tumors to the proprietary anti-cancer compounds of S*BIO. Information on the NUH-NUS TR is outlined.
ACCESSION #
25547359

 

Related Articles

  • Singapore's S*BIO Adds $26M for Phase II Studies in Cancer. Hollingsworth, Catherine // BioWorld Today;10/21/2008, Vol. 19 Issue 205, p1 

    The article reports that S*BIO Pte. Ltd. has raised $26 million to fund phase II trials for the SB939 and SB1518 cancer drugs in 2008. The financing was led by Bio*One Capital, a member of the Singapore Economic Development Authority and Aravis Venture. In a statement, chief executive Jan Anders...

  • Correction.  // BioWorld Today;4/6/2007, Vol. 18 Issue 67, p2 

    A correction to the misidentification of the location of the headquarters of the company S*BIO Pte. Ltd. that was published in the April 4, 2007 issue is presented.

  • S*BIO Adds $26M for Phase II Cancer Studies.  // Bioworld Week;10/27/2008, Vol. 16 Issue 43, p3 

    The article reports on the $26 million funds raised by S☆BIO Pte. Ltd. in 2008. The company raised $26 million in a Series B financing round, which will be used mainly to move its lead compound for cancer, SB939 and SB1518, into Phase II trials. SB939, currently in Phase I testing in both...

  • S*BIO INITIATES CLINICAL TRIAL OF NOVEL ANTI-CANCER DRUG.  // Worldwide Biotech;Aug2007, Vol. 19 Issue 8, p1 

    The article reports that the clinical trial of the novel anti-cancer drug was initiated by the S*BIO Pte Ltd. in Singapore. The SB939 is a histone deacetylase (HDAC) inhibitor which is a targeted anti-cancer therapeutics. The SB939 Phase I trial was conducted to determine its pharmacokinetic and...

  • CLINIC ROUNDUP.  // BioWorld Today;9/19/2008, Vol. 19 Issue 183, p7 

    This section offers news briefs on the pharmaceutical industry. Avigen Inc. has completed the double-blind portion of its Phase IIb trial for AV650 used in the treatment of spasticity linked to multiple sclerosis. Positive results were reported by Incyte Corp. from Phase IIa trials of topical...

  • Tragara Pays $112M to Develop S*BIO Compound.  // Bioworld Week;1/26/2009, Vol. 17 Issue 4, p3 

    The article reports on the $112 million deal between pharmaceutical companies S*BIO Pte. Ltd. and Tragara Pharmaceuticals Inc. in January 2009. The agreement signifies their collaborative effort in developing potential treatment for blood cancer and solid tumors. The project will initially focus...

  • European Haematology Association.  // BioWorld Today;6/15/2010, Vol. 21 Issue 114, p4 

    The article reports on the Phase I/II dose escalation trial of S*BIO Pte. Ltd.'s oral JAK2 inhibitor SB1518 which drew positive safety, tolerability and pharmacokinetic/pharmacodynamic findings.

  • Agilent Technologies and National University of Singapore Sign Research Collaboration Agreement for Lipidomics Research.  // Biomedical Market Newsletter;4/30/2011, p131 

    The article reports on the partnership of Agilent Technologies Inc. and the National University of Singapore (NUS) to develop expertise and knowledge in the field of analytical lipidomics. It states that the partnership aims to develop workflow solutions to allow researchers to more accurately...

  • This Biotech Finds Its Stride With Kidney Cancer Treatment. BERARDI, ERICA // Investors Business Daily;7/7/2017, p8 

    The article focuses on the achievements of biotech company Exelixis including posting first-time operating profit, confirming the effectiveness of its compound for treating kidney cancer and retiring its debts. The partnerships of the company with Bristol-Myers Squibb (BMY) and Roche Holding is...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics